Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Triple-Negative Breast Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT05422794
What this trial is testing

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Triple-Negative Breast Carcinoma+2 more
National Cancer Institute (NCI) 57
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07244874
What this trial is testing

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

Who this might be right for
TNBC - Triple-Negative Breast CancerPD-L1 Positive
Tianjin Medical University Cancer Institute and Hospital 41
Early research (Phase 1)Active Not RecruitingNCT04491942
What this trial is testing

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Who this might be right for
Advanced Bile Duct CarcinomaAdvanced Breast CarcinomaAdvanced Cervical Carcinoma+31 more
National Cancer Institute (NCI) 74
Testing effectiveness (Phase 2)Study completedNCT03383679
What this trial is testing

Study on Androgen Receptor and Triple Negative Breast Cancer

Who this might be right for
Breast Cancer FemaleTriple Negative and Androgen Receptor Positive
UNICANCER 94
Testing effectiveness (Phase 2)UnknownNCT04129996
What this trial is testing

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT05852691
What this trial is testing

Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 83
Testing effectiveness (Phase 2)WithdrawnNCT03326258
What this trial is testing

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmEstrogen Receptor NegativeGPNMB Positive+15 more
National Cancer Institute (NCI)
Early research (Phase 1)Ended earlyNCT02706392
What this trial is testing

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmMetastatic Lung Non-Small Cell Carcinoma+10 more
Fred Hutchinson Cancer Center 21
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07623642
What this trial is testing

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

Who this might be right for
Uterine Cervical NeoplasmsTriple Negative Breast NeoplasmsProstatic Neoplasms+8 more
GV20 Therapeutics 227
Large-scale testing (Phase 3)Study completedNCT04148911
What this trial is testing

Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer
Hoffmann-La Roche 184
Early research (Phase 1)Study completedNCT00576654
What this trial is testing

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmTriple-Negative Breast Carcinoma+1 more
National Cancer Institute (NCI) 73
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07762703
What this trial is testing

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

Who this might be right for
Triple-Negative Breast Cancer (TNBC)
BreakBio Corp 10
Testing effectiveness (Phase 2)UnknownNCT05670925
What this trial is testing

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 46
Testing effectiveness (Phase 2)Study completedNCT04464174
What this trial is testing

Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
MedSIR 54
Large-scale testing (Phase 3)Looking for participantsNCT07111832
What this trial is testing

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Who this might be right for
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 400
Testing effectiveness (Phase 2)Study completedNCT00633464
What this trial is testing

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Who this might be right for
Triple Negative Locally Advanced Non-resectable Breast CancerMetastatic Breast Cancer
R-Pharm 79
Testing effectiveness (Phase 2)WithdrawnNCT05539365
What this trial is testing

Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+1 more
Roswell Park Cancer Institute
Testing effectiveness (Phase 2)WithdrawnNCT05233696
What this trial is testing

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

Who this might be right for
Triple Negative Breast CancerLocally Advanced Breast CancerUnresectable Breast Carcinoma+2 more
University of Colorado, Denver
Not applicableActive Not RecruitingNCT07018427
What this trial is testing

Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Who this might be right for
Breast NeoplasmsTriple Negative Breast CancerHR+, HER2-, Advanced Breast Cancer+1 more
Peking University Cancer Hospital & Institute 70
Large-scale testing (Phase 3)Active Not RecruitingNCT06382142
What this trial is testing

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)

Who this might be right for
Triple-Negative Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 418
Next Page